Article

Ganglioside complexes as new target antigens in Guillain-Barré syndrome.

Third Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
Annals of Neurology (Impact Factor: 11.19). 11/2004; 56(4):567-71. DOI: 10.1002/ana.20222
Source: PubMed

ABSTRACT Antibodies specific for a complex of gangliosides GD1a and GD1b (GD1a/GD1b) were found in sera from eight of 100 patients with Guillain-Barre syndrome (GBS) by the use of enzyme-linked immunosorbent assay and thin-layer chromatogram immunostaining. Those sera also had antibody activities to such ganglioside complexes as GD1a/GM1, GD1b/GT1b, and GM1/GT1b but had little or no reactivity to the each isolated antigen. Clustered epitopes of the ganglioside complex in the plasma membrane may be targeted by such an antibody, and interaction between the antibody and ganglioside complex may induce the neuropathy.

0 Bookmarks
 · 
77 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gangliosides, N-acetylneuraminic acid (sialic acid)-bearing glycosphingolipids, are believed to reside in clusters within membrane microdomains, called lipid rafts or glycosynapse. Recent studies demonstrated that antiganglioside antibodies play an important role in the pathogenesis of Guillain-Barré syndrome (GBS) and Fisher syndrome (FS). The anti-GM1 antibodies are likely to damage peripheral nerves through complement activation with dysfunction of voltage-gated sodium channels. Some antiganglioside antibodies may cause dysfunction of voltage-gated calcium channels without complement activation. Clustered epitopes of ganglioside complexes (GSCs) consisting of two gangliosides can be targeted by serum antibodies in GBS and FS. Anti-GD1a/GD1b complex antibodies are associated with severe GBS. Approximately 50% of FS patients have antibodies to GSCs containing GQ1b or GT1a. Various glycolipids including GSCs may form complex glycolipid environment in the cell membrane, regulating the accessibility and the avidity of antiganglioside antibodies. In addition to antibody specificity, the glycolipid environment or specific distribution of target gangliosides in peripheral nervous system can influence pathogenic effects of antiganglioside antibodies in GBS and FS. Conformational and functional analyses of glycoepitopes of GSCs in the biological membrane will provide new vistas to research on antibody-antigen interaction in GBS, and shed light on microdomain function mediated by carbohydrate-to-carbohydrate interaction.
    Japanese Journal of Clinical Immunology 01/2011; 34(1):29-39.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The glycome is defined as the glycan repertoire of cells, tissues, and organisms, as found under specified conditions. The vastly diverse glycome is generated by a nontemplate driven biosynthesis, which is indirectly encoded in the genome, and very dynamic. Due to this overwhelming diversity, glycomic analysis must be approached at different hierarchical levels of complexity. In this review five such levels of complexity and the experimental approaches used for analysis at each level are discussed for a subclass of the glycome: the sialome. The sialome, in analogy to the canopy of a forest, covers the cell membrane with diverse array of complex sialylated structures. Sialome complexity includes modification of sialic acid core structure (the leaves and flowers), the linkage to the underlying sugar (the stems), the identity, and arrangement of the underlying glycans (the branches), the structural attributes of the underlying glycans (the trees), and finally, the spatial organization of the sialoglycans in relation to components of the intact cell surface (the forest). Understanding the full complexity of the sialome thus requires combined analyses at multiple levels, that is, the sialome is far more than the sum of its parts.
    Omics: a journal of integrative biology 08/2010; 14(4):455-64. · 2.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic autoimmune neuropathy, of which the precise pathogenetic mechanisms have not yet been elucidated. Recently, the elevated titer of the antibodies to contactin-1, a protein in axoglial junction, has been reported in a subset of CIDP patients. The antibody-positive patients shared common clinical features. The antibodies to contactin-1 might be a good serological marker, and possibly have a pathogenic role in a subgroup of CIDP patients. Examination of the serum antibodies against glycolipids, myelin proteins and proteins in axoglial junctions for the same cohort of patients should be carried out in future.
    Clinical and Experimental Neuroimmunology. 02/2014; 5(1).